Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC increased its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) by 25.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 48,087 shares of the company’s stock after purchasing an additional 9,754 shares during the quarter. SG Americas Securities LLC’s holdings in Arcutis Biotherapeutics were worth $670,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Point72 DIFC Ltd purchased a new position in shares of Arcutis Biotherapeutics during the 3rd quarter worth approximately $25,000. Algert Global LLC acquired a new position in Arcutis Biotherapeutics during the second quarter worth $97,000. Erste Asset Management GmbH purchased a new position in Arcutis Biotherapeutics in the third quarter worth $104,000. LVW Advisors LLC acquired a new stake in Arcutis Biotherapeutics in the fourth quarter valued at $166,000. Finally, Victory Capital Management Inc. boosted its position in shares of Arcutis Biotherapeutics by 9.9% during the 3rd quarter. Victory Capital Management Inc. now owns 12,843 shares of the company’s stock worth $119,000 after purchasing an additional 1,155 shares in the last quarter.

Insider Transactions at Arcutis Biotherapeutics

In related news, Director Howard G. Welgus sold 10,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $12.51, for a total transaction of $125,100.00. Following the completion of the sale, the director now owns 161,944 shares of the company’s stock, valued at approximately $2,025,919.44. This represents a 5.82 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Patrick Burnett sold 16,023 shares of the firm’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $10.14, for a total transaction of $162,473.22. Following the completion of the transaction, the insider now directly owns 128,669 shares in the company, valued at approximately $1,304,703.66. This represents a 11.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 68,291 shares of company stock worth $841,466 over the last quarter. 9.50% of the stock is currently owned by insiders.

Arcutis Biotherapeutics Stock Down 0.4 %

ARQT stock opened at $13.67 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.46 and a quick ratio of 2.38. Arcutis Biotherapeutics, Inc. has a 12 month low of $5.38 and a 12 month high of $16.20. The firm has a market capitalization of $1.60 billion, a PE ratio of -7.64 and a beta of 1.30. The company’s 50 day simple moving average is $13.50 and its 200-day simple moving average is $11.02.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its earnings results on Wednesday, November 6th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.09. The firm had revenue of $44.76 million during the quarter, compared to the consensus estimate of $38.05 million. Arcutis Biotherapeutics had a negative net margin of 140.97% and a negative return on equity of 119.11%. Equities analysts expect that Arcutis Biotherapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

ARQT has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 price target on shares of Arcutis Biotherapeutics in a report on Thursday, November 7th. Mizuho lifted their price target on shares of Arcutis Biotherapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, January 7th. Finally, HC Wainwright restated a “buy” rating and issued a $19.00 price target on shares of Arcutis Biotherapeutics in a report on Monday, January 13th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Arcutis Biotherapeutics has an average rating of “Moderate Buy” and a consensus target price of $16.60.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.